BIOMARIN PHARMACEUTICAL INC (BMRN) Form 8-K — Sep 30, 2026

$BMRNForm 8-KItems 1.01Filed Sep 30, 2026, 4:15 PM ET0001628280-26-063981Original filing

BioMarin entered into a definitive Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing the August 28 binding term sheet and dismissing all pending patent litigation between the parties with prejudice. Under the agreement, BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel) for all indications, including achondroplasia and hypochondroplasia.

Key figures

Effective date: August 28, 2026
Royalty end date: May 2030
Royalty us net sales: 20%
Royalty eu brazil korea net sales: 18%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.